Understanding NTRK Treatment Options for Prostate Cancer

Targeted cancer medicines are increasingly guided by genetic changes in a tumour rather than by where the cancer started. NTRK is one of the better-known examples of this approach, because medicines that block TRK proteins can work across multiple cancer types when an NTRK fusion is driving growth. In prostate cancer, NTRK fusions are rare, so the main challenge is knowing when testing is appropriate and how results affect treatment choices.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

NTRK and Prostate Cancer: An Overview

NTRK refers to three genes: NTRK1, NTRK2, and NTRK3. In some cancers, a piece of an NTRK gene becomes abnormally joined to another gene, creating an NTRK fusion. This fusion can produce an overactive TRK protein that signals the cancer to grow.

In prostate cancer, these fusions are not common. That matters because NTRK testing is usually considered when it may realistically change treatment decisions, such as in metastatic disease, unusual pathology, or when standard options have been used or are unsuitable. Your oncology team may also consider broader genomic testing that includes NTRK as part of a panel, especially when treatment decisions depend on identifying actionable biomarkers.

Available Treatments Targeting NTRK

If a tumour is confirmed to have an NTRK fusion, TRK inhibitor therapy may be considered. Two widely recognised TRK inhibitors used internationally for NTRK fusion-positive solid tumours are larotrectinib and entrectinib. They are tumour-agnostic in intent, meaning eligibility depends on the presence of the fusion rather than the tumour’s location.

For people with prostate cancer, TRK inhibitors are typically discussed in the context of advanced or metastatic disease and after careful review of overall health, prior treatments, possible drug interactions, and the strength of the evidence that the fusion is genuinely driving the tumour. In the UK, access can depend on current national guidance, commissioning arrangements, and whether treatment is provided through routine pathways or research studies. Clinicians commonly check up-to-date recommendations and local formulary status because availability can differ across the UK nations and can change over time.

How NTRK Testing Works

NTRK testing is usually done on tumour tissue (for example from a biopsy or surgery sample) and sometimes via a blood test that looks for circulating tumour DNA. The best method can depend on how much tissue is available, the quality of the sample, and what other biomarkers need to be assessed.

Common approaches include next-generation sequencing (NGS) panels, which can search for many genetic changes at once and can detect NTRK fusions when the panel is designed to do so. Some centres may use immunohistochemistry (IHC) as a screening tool to look for TRK protein expression, followed by confirmatory testing, since protein expression alone does not always prove a fusion. Other confirmatory methods can include fluorescence in situ hybridisation (FISH) or RNA-based sequencing, which can be particularly helpful for detecting gene fusions.

Because NTRK fusions are rare in prostate cancer, a key practical point is ensuring the result is robust and clinically meaningful. Your team may also consider whether the same sample should be tested for additional biomarkers that influence prostate cancer management, and whether re-biopsy is needed if the cancer has changed over time.

Potential Side Effects of NTRK Treatments

Like other targeted therapies, TRK inhibitors can cause side effects that range from mild to serious. Many people experience manageable symptoms, but monitoring is important, particularly early in treatment and after dose changes.

Reported side effects can include tiredness, dizziness, nausea, constipation or diarrhoea, reduced appetite, weight gain, and changes in liver blood tests. Because TRK signalling is involved in the nervous system, some people may experience neurological effects such as dizziness, unsteadiness, or sensory changes. Less commonly, more serious problems can occur, including significant liver toxicity or effects on heart rhythm, depending on the medicine and individual risk factors.

For someone already dealing with symptoms from advanced prostate cancer or other treatments, it is helpful to review how side effects might overlap (for example fatigue, appetite changes, or neuropathy) and how they would be managed. This typically includes scheduled blood tests, symptom tracking, and dose adjustment where appropriate.

The Role of Clinical Trials in NTRK Therapy Development

Clinical trials are central to improving how NTRK-targeted therapy is used, especially in tumour types where NTRK fusions are uncommon. Many NTRK studies are basket trials, which enrol people based on a shared genetic alteration across different cancers. This design helps researchers understand how well TRK inhibitors work in rare fusion-positive groups.

Trials also address what happens when cancers become resistant. Resistance can develop through new mutations in the NTRK gene that prevent the drug from binding effectively, or through alternate growth pathways that bypass TRK signalling. Newer investigational TRK inhibitors and combination strategies are being studied to overcome these mechanisms.

For UK patients, clinical trial availability depends on location, eligibility criteria, prior treatments, and whether a trial site is open and recruiting. Even when a trial is not suitable, the evidence generated by trials helps shape future guidance on testing strategies, sequencing of therapies, and monitoring.

In practice, the most important takeaway is that NTRK is a specific, actionable biomarker, but it is not a routine driver of most prostate cancers. When present, it can meaningfully influence treatment discussions, and when absent, it helps focus attention on other established pathways and options. A clear explanation of the test method, the confidence in the result, and how it would change management is the foundation of good decision-making.